Featured Research

from universities, journals, and other organizations

Humanin Peptide May Be New Drug Target For Diabetes, Alzheimer's Disease

Date:
April 23, 2009
Source:
Federation of American Societies for Experimental Biology
Summary:
Recent studies have shown that the mitochondrial peptide Humanin (HN) protects against neuronal cell death such as happens in Alzheimer's disease. Researchers report that a small infusion of HN is a potent regulator of insulin metabolism, significantly improving overall insulin sensitivity and sharply decreasing the glucose levels of diabetic rats.

Recent studies have shown that the mitochondrial peptide Humanin (HN) protects against neuronal cell death such as happens in Alzheimer's disease. Now, in a study presented April 22 at Experimental Biology 2009 in New Orleans, Dr. Nir Barzilai reports that a small infusion of HN is the most potent regulator of insulin metabolism that his research team has ever seen, significantly improving overall insulin sensitivity and sharply decreasing the glucose levels of diabetic rats.

The finding is the first evidence of a role for HN in glucose metabolism and provides new insight into how this metabolism may be involved in the development of seemingly diverse age-related diseases such as Type 2 Diabetes Mellitus and Alzheimer's. The finding also provides support for the growing understanding that the brain (not just the pancreas, liver and other peripheral organs) is heavily involved in glucose metabolism.

Furthermore, says Dr. Barzilai, the Ingeborg and Ira Leon Rennert Chair of Aging Research and Director of the Institute for Aging Research at the Albert Einstein College of Medicine, the power of HN on insulin action suggests a new therapeutic approach to diabetes. Further understanding of how HN interactions with the growth hormone/insulin-like growth factor system may also lead to strategies to protect against age-related diseases including Alzheimer's.

Dr. Barzilai's presentation at Experimental Biology 2009 is part of the scientific program of the American Society for Biochemistry and Molecular Biology.

Dr. Barzilai is internationally known as a leading discoverer of longevity genes, especially those he has identified in a well-established group of almost 500 Ashkenazi Jews, aged 95 to 112, and their families. Last year, he reported that some of the oldest in this group have mutations in the gene for insulin-like growth factor 1 (IGF-1) receptor, genetic alterations that have been shown to prolong life span in worms and some mammals. In this Experimental Biology presentation, he reports that, while the production of HN generally decreases as people age, it decreases less in the centenarians and is the highest in their offspring. Studies are now underway at the Institute for Aging Research to determine if the centenarians have a mutation in the HN gene in the mitochondria.

How do these genes fit together? Although there is still much to learn, says Dr. Barzilai, his team increasingly understands how HN interacts with the GH/IGF system. In earlier studies, the team found that insulin-like growth factor binding protein-3 (IGFBP-3) binds Humanin and tempers its effects on promotion of cell survival.

In this new study, the effects of HN on insulin action also were found to be tempered by IGFBP-3. Inhibiting IGFBP-3 allowed the peptide to exert a more potent effect. That suggests a drug target, says Dr. Barzilai.

He says that in this preclinical testing period, it is still too soon to know how HN would perform in humans, but he believes the naturally occurring peptide's ability to preserve cells is promising. One concern of anti-diabetic drugs is increased risk for cardiovascular disease. When Dr. Barzilai's team administered Humanin to rats before or after they were induced to have heart attacks, however, the area of infarction (area of dead cells caused by lack of blood) actually decreased by almost 50 percent, compared to that in rats not given the peptide.

Funding for the study came from the National Institute on Aging and the Paul Glenn Foundation.


Story Source:

The above story is based on materials provided by Federation of American Societies for Experimental Biology. Note: Materials may be edited for content and length.


Cite This Page:

Federation of American Societies for Experimental Biology. "Humanin Peptide May Be New Drug Target For Diabetes, Alzheimer's Disease." ScienceDaily. ScienceDaily, 23 April 2009. <www.sciencedaily.com/releases/2009/04/090422103546.htm>.
Federation of American Societies for Experimental Biology. (2009, April 23). Humanin Peptide May Be New Drug Target For Diabetes, Alzheimer's Disease. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/04/090422103546.htm
Federation of American Societies for Experimental Biology. "Humanin Peptide May Be New Drug Target For Diabetes, Alzheimer's Disease." ScienceDaily. www.sciencedaily.com/releases/2009/04/090422103546.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins